LY3437943 ships as a lyophilized powder across five vial masses, 10 mg, 20 mg, 30 mg, 48 mg and 60 mg, plus a two-component blend vial paired with AM833. The concentration arithmetic is the same simple relationship used for any lyophilized peptide, mass divided by diluent volume equals concentration, but the wider mass range on LY3437943's vial lineup makes it worth working through each size explicitly rather than relying on a single example. This guide covers that math, the blend vial's two-component version of it, and the handling details specific to a fatty-acid-conjugated, more hydrophobic peptide like this one.
| Vial mass | Diluent volume | Resulting concentration |
|---|---|---|
| 10 mg | 2 mL | 5 mg/mL |
| 20 mg | 2 mL | 10 mg/mL |
| 30 mg | 3 mL | 10 mg/mL |
| 48 mg | 3 mL | 16 mg/mL |
| 60 mg | 3 mL | 20 mg/mL |
How does the basic reconstitution formula apply across this vial range?
Concentration equals mass divided by volume, the same relationship covered in general terms in reconstituting lyophilized peptides. What changes across LY3437943's vial lineup is simply the numerator. A lab standardizing on a fixed diluent volume across every vial size will get a different concentration from each one, as the table above shows for a 2 mL or 3 mL fill. A lab that instead wants a fixed target concentration regardless of vial size needs to solve for volume instead: volume equals mass divided by target concentration. For a 48 mg vial and a target of 10 mg/mL, that is 48 divided by 10, or 4.8 mL of diluent. The arithmetic itself does not change with vial size; only which variable is fixed and which is solved for does.
Why does Homegrown supply LY3437943 across five vial masses instead of one?
Different study designs draw down a reconstituted vial at different rates, and the shelf life of a reconstituted solution is finite, so matching vial mass to the actual material a protocol will use before the solution's usable window closes is the main reason to pick one size over another. That trade-off, along with the concentration and waste arithmetic behind it, is covered in depth in choosing the right vial size for a study. The short version for LY3437943 specifically: the 10 mg and 20 mg vials suit smaller-scale bench work and pilot assays, while the 48 mg and 60 mg vials suit protocols that consume more material across a longer series without introducing a second lot partway through.
How does the concentration math change for the blend vial?
The LY3437943-AM833 blend vial lists both components by mass in the same vial, 12.5 mg of LY3437943 and 2.5 mg of AM833. Reconstituting that vial with 2 mL of diluent does not produce a single combined concentration; it produces two separate concentrations in the same solution, 6.25 mg/mL of LY3437943 and 1.25 mg/mL of AM833. Each component should be tracked separately in lab notes, the same principle covered for two-component vials generally in the site's blend-concentration guide, since treating a blend vial's total mass as if it were one compound is a common arithmetic error. Background on why AM833 is paired with LY3437943 at all, and on the amylin-receptor pathway it contributes, is covered in LY3437943 and AM833 explained.
Does LY3437943's fatty diacid chain change anything about handling?
The chain that gives LY3437943 its albumin-binding property, described in more detail in the site's article on the molecule's structure, also makes the finished peptide noticeably more hydrophobic than an unmodified linear peptide of comparable size. At the bench that means paying closer attention to complete dissolution: swirl or roll the vial gently rather than shaking it, and expect dissolution to take a little longer than it would for a small, unmodified peptide. Foaming or a persistently cloudy solution after several minutes is a reason to log the lot and stop rather than proceed. Manning and colleagues' review of protein and peptide pharmaceutical stability lays out the general chemistry behind why mechanical stress and incomplete dissolution matter for a lipidated peptide in solution, covering aggregation and interfacial denaturation pathways relevant well beyond the specific molecules they profile (Manning et al., 2010).
What diluent and storage practices apply to LY3437943 specifically?
Bacteriostatic water is the standard multi-draw diluent choice for the same reason it is standard for other lyophilized research peptides: the benzyl alcohol it contains suppresses bacterial growth once the vial stopper has been punctured for repeated draws. A 30 mL bottle covers reconstitution across several vials, and a reconstitution kit bundles the diluent with the sterile syringes and vial adapters a bench typically needs for this step. Once reconstituted, LY3437943 behaves like other reconstituted peptides in terms of storage: refrigerate, protect from light, date the vial at first puncture, and aliquot before freezing if a solution needs to be held longer than the refrigerated window supports, since freeze-thaw cycling is damaging to peptides generally. Full guidance on those windows and on the underlying degradation chemistry is in peptide storage and stability.
Where can a lab check the exact mass and lot details before doing this math?
The concentration math above assumes the vial's labeled mass is accurate for the specific lot in hand, which is worth confirming against the certificate of analysis before running the numbers, since net peptide content can shift the true peptide mass slightly relative to the label. Homegrown posts lot-specific specifications, including net peptide content, for each LY3437943 vial size and for the LY3437943-AM833 blend vial on their respective product pages, starting with the LY3437943 product page and the LY3437943-AM833 product page. The site's dedicated guide to reading a certificate of analysis walks through how to interpret that net peptide content figure once it is in hand.
Frequently asked questions
Does a larger LY3437943 vial require a different reconstitution technique?
No. The technique, room-temperature equilibration before opening, an alcohol wipe on the stopper, slow addition of diluent down the vial wall, and gentle mixing rather than shaking, is the same across all five vial masses. Only the arithmetic for the resulting concentration changes with mass and diluent volume.
Can the 48 mg or 60 mg vial be split into two smaller working aliquots after reconstitution?
Yes, and for a vial that will not be used up quickly this is standard practice: reconstitute, then divide the solution into labeled, dated aliquots and freeze what will not be used within the refrigerated window, rather than repeatedly freeze-thawing a single larger volume.
Is the blend vial's diluent volume the same as a single-component vial of similar total mass?
Not necessarily. The right diluent volume for a blend vial depends on the target concentration a protocol needs for each component individually, since the two peptides are present at different masses (12.5 mg and 2.5 mg in Homegrown's LY3437943-AM833 vial) and a single diluent volume produces two different concentrations at once.
Why does a more hydrophobic, fatty-acid-conjugated peptide take longer to dissolve?
The fatty diacid chain that gives LY3437943 its albumin-binding property also makes the molecule less water-soluble than an unmodified peptide of similar size, which is a documented general property of acylated, protracted peptide hormones (Jonassen et al., 2012). Gentle mixing and a little patience, rather than more vigorous agitation, is the appropriate response.
What is the first sign a LY3437943 vial did not reconstitute properly?
Persistent cloudiness or visible particulate that does not clear after several minutes of gentle mixing, or foam that suggests protein denaturation from excessive agitation. Either is a reason to note the lot and hold off on using that preparation in an assay.
References
- Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed 20143256.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340.
- Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104-2114. PubMed 22485010.
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.
